New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2014
07:40 EDTHTWR, THORHeartWare remains well positioned in LVAD market, says Leerink
Leerink attributes HeartWare's (HTWR) disappointing Q4 sales to company-specific issues and broader market weakness. The firm expects competitor Thoratec (THOR) to trade lower on the potential for LVAD market weakness, but keeps Outperform ratings on companies. Leerink still views Thoratec as well positioned in the LVAD market and sees potential catalysts in 2014.
News For HTWR;THOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:00 EDTHTWRHeartWare reports Q3 EPS (64c), consensus (65c)
Subscribe for More Information
October 28, 2014
10:12 EDTTHOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:40 EDTTHORThoratec downgraded to Equal Weight from Overweight at Barclays
Subscribe for More Information
October 21, 2014
15:00 EDTHTWRUpdate suggests HeartWare CE mark trial on track, says Wells Fargo
Wells Fargo said the posting for HeartWare's MVAD CE Mark trial, which had not been changed since April 2013, was updated on October 16 and now indicates the trial is scheduled to start in April 2015. Wells expects HeartWare to update on MVAD on its Q3 call next week, but the firm said that it does not expect any major surprises based on the updated posting. Wells Fargo maintains its Market Perform rating on HeartWare.
October 17, 2014
10:16 EDTTHORHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use